The state of Florida currently has 132 active clinical trials seeking participants for Lymphoma research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
NCT05260957
Recruiting
The purpose of this research study is to test if a combination treatment of chimeric antigen receptor (CAR) T-cell therapy, Mosunetuzumab, and Polatuzumab Vedotin will result in tumor reduction.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/17/2024
Locations: University of Miami, Miami, Florida
Conditions: Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma
Register for Updates
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
NCT05664217
Recruiting
This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Chimeric antigen (CAR)-T cell product consists of genetically engineered T-cells, modified to recognize C... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma
Register for Updates
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
NCT05700149
Recruiting
International retrospective observational cohort study aimed to describe a molecular classification for NMZL.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/03/2024
Locations: University of Miami, Miami, Florida
Conditions: Nodal Marginal Zone Lymphoma
Register for Updates
Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
NCT02737046
Recruiting
The investigators propose to use Belinostat in combination with AZT as consolidation therapy for the treatment of ATLL.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/29/2023
Locations: University of Miami, Miami, Florida
Conditions: Adult T-cell Leukemia-Lymphoma, ATLL
Register for Updates
HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903
NCT04975698
Recruiting
This is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT) followed by administration of HST-NEETs for treatment of HIV associated lymphoma
Gender:
All
Ages:
15 years and above
Trial Updated:
12/21/2023
Locations: Miami Cancer Institute, Miami, Florida +1 locations
Conditions: HIV Associated Lymphoma
Register for Updates
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
NCT04970901
Recruiting
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/19/2023
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida +2 locations
Conditions: B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Register for Updates
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
NCT05714345
Recruiting
The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647 combined with fludarabine and cyclophosphamide compared to fludarabine and cyclophosphamide alone in a lymphodepletion regimen prior to ALLO-501A CAR T therapy in adults with relapsed or refractory large B-cell lymphoma
Gender:
All
Ages:
18 years and above
Trial Updated:
12/13/2023
Locations: University of Florida Health Shands Cancer Hospital, Gainesville, Florida
Conditions: Relapsed/Refractory Large B Cell Lymphoma
Register for Updates
A Registry for People With T-cell Lymphoma
NCT05978141
Recruiting
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
Gender:
All
Ages:
All
Trial Updated:
12/06/2023
Locations: University of Miami (Data Collection Only), Miami, Florida +1 locations
Conditions: T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
Register for Updates
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
NCT05968963
Recruiting
The goal of this study is to pilot test an Electronic Health Mindfulness-based Music Therapy Intervention (eMBMT) intervention to improve health-related quality of life (HRQoL) and reduce symptom burden of patients undergoing allogeneic stem cell transplantation (allo-SCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: University of Miami, Miami, Florida
Conditions: Stem Cell Transplantation, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
Register for Updates
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT03516617
Recruiting
This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known wh... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496
Recruiting
This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/22/2023
Locations: University Of Miami ., Miami, Florida
Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
Register for Updates
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
NCT03666000
Recruiting
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-optimization study to evaluate the safety and clinical activity of PBCAR0191 in adults with r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N) and identify a treatment regimen most likely to result in clinical efficacy while maintaining a favorable safety profile.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: H. Lee Moffitt Cancer Center, Tampa, Florida
Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Register for Updates